61703-38-6

Usage

Uses

Used in Pharmaceutical Industry:
2-Pyrrolidinecarboxamide,4-hydroxy-,(2S,4R)-(9CI) is used as a potential pharmaceutical candidate for various applications due to its unique structure and properties. Its 4-hydroxy group and stereochemistry may contribute to its potential medicinal uses, and further research and studies may be conducted to explore its therapeutic potential.

Upstream product

• 68172-39-4 benzyl (2S,4R)-4-hydroxypyrrolidine-2-carboxylate 
• 1499-56-5 (R)-4-hydroxy-L-proline ethyl ester 
• 13726-69-7 (2S,4R)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid 
• 51-35-4 4R-4-hydroxyproline 

Downstream Products

• 114358-08-6 (2S,4R)-1-methyl-2-carbamoyl-4-hydroxypyrrolidine 
• 1163704-98-0 (2S,4R)-4-hydroxy-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({5-[4-methanesulfonyl-3-(2-propyl-imidazol-1-yl)-phenyl]-4-methyl-thiazol-2-yl}-amide) 

Relevant academic research and scientific papers

2-Carboxamide Cycloamino Ureas

The present invention relates to compounds of formula I and salts thereof, wherein the substituents are as defined in the description, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol

Organic Compounds

The present invention relates to compounds of formula I and its salts, wherein the substituents are as defined in the description, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase.

ORGANIC COMPOUNDS

The resent invention relates to a com ound of formula (I) and its salts, wherein the substituents are as defined in the description, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-

QUINAZOLINE DERIVATIVES

The invention concerns quinazoline derivatives of Formula (I) wherein each of R1, R3, R20, X1, X2, Z, W, (a) and (q) have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of turnours which are sensitive to inhibition of erbB receptor tyrosine kinases, particularly EGFR tyrosine kinase.

Beta-lactam compounds

A beta-lactam compound of the formula: STR1 or a pharmaceutically acceptable salt thereof, which is useful as an anti-microbial agent or an intermediate in the synthesis of anti-microbial agents.